Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study

被引：0
|
作者：
Palmedo, H. [1 ]
Eschmann, S. [2 ]
Werner, A. [3 ]
Selinski, I. [4 ]
Moellers, M-O. [5 ]
Kalinovsky, J. [6 ]
Benson, A. [7 ]
Poeppel, T. [8 ]
机构：
[1] Johanniter Hosp, Canc Ctr, Dept Nucl Med, Bonn, Germany
[2] Marien Hosp, Nucl Med, Stuttgart, Germany
[3] Radiol Schwetzingen, Radiol, Schwetzingen, Germany
[4] Goethe Univ Hosp Frankfurt, Ctr Radol, Frankfurt, Germany
[5] Klinikum Westfalen, Nucl Med, Dortmund, Germany
[6] Bayer Consumer Care Switzerland, Global Med Affairs, Basel, Switzerland
[7] Bayer HealthCare Pharmaceut, Stat, Whippany, NJ USA
[8] Univ Hosp Essen, Nucl Med, Essen, Germany
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
860P
引用
收藏
页码：336 / 336
页数：1
相关论文
共 50 条
  • [31] Radium-223 In The Treatment Of Metastatic Castration-Resistant Prostate Cancer
    Vazzana, C.
    Morano, S.
    Di Lascio, A.
    Grana, C.
    Chinol, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S880 - S880
  • [32] RADIUM-223: TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    James, D.
    Hillery, R.
    Freeman, L.
    Kumari, A.
    Kearney, N.
    INTERNAL MEDICINE JOURNAL, 2016, 46 : 30 - 31
  • [33] Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets)
    Sun, Y.
    Shi, H.
    Chen, C. -H.
    Lee, J. L.
    Kang, T. W.
    Park, S. H.
    Wu, T. L.
    Ng, Q. S.
    Keam, B.
    Wong, S. C. A.
    Tay, M. H.
    Ding, Q.
    Li, F.
    Ng, D. C. E.
    Liu, X.
    Zhang, Z.
    Guo, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 73 - 74
  • [34] Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with 223Ra: PARABO, a Prospective, Noninterventional Study
    Palmedo, Holger
    Ahmadzadehfar, Hojjat
    Eschmann, Susanne
    Niesen, Andreas
    Schoenberger, Johann
    Barsegian, Vahe
    Liepe, Knut
    Mottaghy, Felix M.
    Guan, Rongjin
    Pinkert, Joerg
    Sandstroem, Per
    Herrmann, Ken
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (09) : 1392 - 1398
  • [35] Real-world safety and effectiveness of radium-223 (223Ra) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated in the US: The non-interventional REASSURE study
    Song, Daniel Y.
    George, Saby
    Zimberg, Shawn
    Nordquist, Luke T.
    Tomaszewski, Jeffrey
    Conti, Peter S.
    Meltzer, Jeffrey
    Verholen, Frank
    Schmall, Anja
    Higano, Celestia S.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Single-Institution Experience With Radium-223 Dichloride (Ra-223) for Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Cox, B. W.
    Wang, L.
    Bradley, T.
    Gu, B.
    Kelley, K.
    Potters, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S470 - S470
  • [37] Radium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Miller, K.
    Heinrich, D.
    O'Sullivan, J. M.
    Carles, J.
    Wirth, M.
    Nilsson, S.
    Huang, L.
    Kalinovsky, J.
    Heidenreich, A.
    Saad, F.
    ANNALS OF ONCOLOGY, 2018, 29 : 287 - 287
  • [38] Use of Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer
    Parker, Chris
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (11) : 723 - 725
  • [39] Radium-223 in metastatic castration resistant prostate cancer
    Vuong, Winston
    Sartor, Oliver
    Pal, Sumanta K.
    ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (03) : 348 - 353
  • [40] First interim results of the Radium-223 (Ra-223) reassure observational study in metastatic castration-resistant prostate cancer (mCRPC): Safety and baseline (BL) characteristics of US patients (Pts) by prior/concomitant treatment (Tx).
    Harshman, Lauren Christine
    Sartor, A. Oliver
    Richardson, Timothy
    Sylvester, John
    Song, Daniel Y.
    Mantz, Constantine
    Brookland, Robert K.
    Perlmutter, Mark
    Given, Robert
    Kalinovsky, Jan
    Babajanyan, Svetlana
    De Sanctis, Yoriko
    Higano, Celestia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345